Skip to content

Avacta Shares Rise As AVA3996 Selected for Pre-Clinical Development

Sam Boughedda trader
Updated 18 Jan 2022

Key points:

  • Avacta shares up 8%
  • AVA3996 selected for preclinical development
  • The pre|CISIONTM chemistry is used to alter chemotherapy drugs
  • Avacta Group PLC Stock Forecast

Shares of Avacta have risen just over 8% Tuesday after the company announced the next pre|CISIONTM drug candidate, AVA3996, has been selected for preclinical development.

The company's pre|CISIONTM chemistry is used to alter chemotherapy drugs to make them inactive in the circulation until they enter the tumour micro-environment where they are then activated by an enzyme.

As a result, Avacta says the platform offers a way to reduce exposure to and improve the safety of cancer drugs by increasing the tolerability of chemotherapies.

Also Read: The Best Healthcare Stocks To Buy

Avacta explained that it reviewed efficacy studies and selected AVA3996 as a candidate for preclinical development. The aim for the company is a Clinical Trial Authorisation (CTA) and Investigational New Drug (IND) filing in the first half of 2023.

The first-in-human Phase 1 clinical trial is forecast to begin in the second half of 2023.

Dr Alastair Smith, CEO of Avacta Group, commented: “We are excited by the early pre-clinical data for AVA3996, the second of Avacta's pre|CISIONTM pro-drugs following on from AVA6000. The pre|CISIONTM platform has the potential to generate a significant pipeline of safer, better tolerated chemotherapies to treat a wide range of cancers. It represents a major commercial opportunity and the principal value driver for the Group.”

Avacta shares are currently trading around the 79p area.

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.